Loading stock data…
$1.97-0.02 (-1.01%)
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. in the Healthcare sector is trading at $1.98 with a market capitalization of $44M. Wall Street consensus targets $5.84 (2 analysts), implying a +195.7% move over the next 12 months. The stock is currently near its 52-week low of $1.79, remaining 32.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.38M↑ | -$3.01M↓ | -$2.45M↑ | -$2.53M↑ | -$3.09M |
| Net Income | -$15.79M↓ | -$1.18M↑ | -$2.31M↓ | -$938,000↑ | -$3.36M |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal ...